Form 4: UNITED THERAPEUTICS CEO Sells Shares
Insider Transaction (Form 4)
Martine A Rothblatt, Chairperson & CEO and a Director of UNITED THERAPEUTICS Corp, sold 1,920 shares of common stock on September 30, 2026.
Summary
- Open-market sale: disposed of 400 Common Stock at $547.29 ($218,918) on September 30, 2026; holds 325,963 after (Indirect).
- Open-market sale: disposed of 280 Common Stock at $548.25 ($153,511) on September 30, 2026; holds 325,683 after (Indirect).
- Open-market sale: disposed of 240 Common Stock at $549.40 ($131,855) on September 30, 2026; holds 325,443 after (Indirect).
- Open-market sale: disposed of 400 Common Stock at $550.47 ($220,187) on September 30, 2026; holds 325,043 after (Indirect).
- Open-market sale: disposed of 160 Common Stock at $551.50 ($88,239) on September 30, 2026; holds 324,883 after (Indirect).
- Open-market sale: disposed of 120 Common Stock at $552.63 ($66,315) on September 30, 2026; holds 324,763 after (Indirect).
- Open-market sale: disposed of 113 Common Stock at $553.78 ($62,577) on September 30, 2026; holds 324,650 after (Indirect).
- Open-market sale: disposed of 207 Common Stock at $554.70 ($114,823) on September 30, 2026; holds 324,443 after (Indirect).
Sentiment
Score: 4
Explanation: StockSavvy.ai views this as a mildly negative but low-conviction signal: an insider sold $1,056,425 of stock under a pre-arranged Rule 10b5-1 plan, which is typically routine.
Insider Transactions
Martine A Rothblatt — Director, Officer (Chairperson & CEO)
Transaction made under a Rule 10b5-1 trading plan.
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-09-30 | Open-market sale | Common Stock | 400 | $547 | $218.9K | 325,963 |
| 2026-09-30 | Open-market sale | Common Stock | 280 | $548 | $153.5K | 325,683 |
| 2026-09-30 | Open-market sale | Common Stock | 240 | $549 | $131.9K | 325,443 |
| 2026-09-30 | Open-market sale | Common Stock | 400 | $550 | $220.2K | 325,043 |
| 2026-09-30 | Open-market sale | Common Stock | 160 | $551 | $88.2K | 324,883 |
| 2026-09-30 | Open-market sale | Common Stock | 120 | $553 | $66.3K | 324,763 |
| 2026-09-30 | Open-market sale | Common Stock | 113 | $554 | $62.6K | 324,650 |
| 2026-09-30 | Open-market sale | Common Stock | 207 | $555 | $114.8K | 324,443 |
Key Dates
| Date | Description |
|---|---|
| 2026-09-30 | Open-market sale (400 shares) |
| 2026-09-30 | Open-market sale (280 shares) |
| 2026-09-30 | Open-market sale (240 shares) |
| 2026-09-30 | Open-market sale (400 shares) |
| 2026-09-30 | Open-market sale (160 shares) |
| 2026-09-30 | Open-market sale (120 shares) |
| 2026-09-30 | Open-market sale (113 shares) |
| 2026-09-30 | Open-market sale (207 shares) |
Keywords
insider transaction, Form 4, UTHR, UNITED THERAPEUTICS Corp, bearish, Martine A Rothblatt
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.